

CROSS-INDUSTRY Organizations

An introduction to the Inhalation Drug Delivery Association (IDDA)

Anny Shen, MD

On behalf of the Inhalation Drug Delivery Association (IDDA)



Membership and organization

The Inhalation Drug Delivery Association (IDDA) is a non-profit organization, established on November 8th, 2013 in Nanjing, China. The IDDA membership includes pharmaceutical research and manufacturing enterprises, universities and hospitals specializing in inhalation drugs and clinical therapy.

IDDA follows the drug laws and regulations issued by the Chinese government and aims to improve the capabilities of the Chinese inhalation drug industry by promoting and following globally-accepted standards in the Chinese inhalation drug industry and clinics.

IDDA has two teams; the first concentrates on inhalation drug delivery technologies, including inhalation product quality and inhalation technology research. The second team works on inhalation products market research and inhalation therapy education for asthmatic and COPD patients.

Initial conferences

The first IDDA symposium was held on November 8-9, 2013, with approximately 90 attendees from more than 40 Chinese pharmaceutical companies, universities, research institutes, CFDA drug quality control laboratories, hospitals and the Chinese Pharmacopoeia Commission. The IDDA was formally established at this conference, 19 IDDA committee members were elected and eight scientific presentations were given. These focused on research and development and on application of inhalation products, product quality, regulation, the China Pharma-

copoeia (2015 edition) update for inhalation products, inhalation technology and therapy, asthma/COPD treatment with inhaled drugs, and the status of chlorofluorocarbon (CFC) to hydrofluoroalkane (HFA) transition in China.

On October 17-19, 2014, the IDDA, together with the Pharmaceutical Industry Information Centre of China Institute of Pharmaceutical Industry and the Nanjing University of Chinese Medicine, organized the second IDDA conference. More than 200 attendees, including domestic and invited international speakers, participated in this event. The two-day presentations covered a comprehensive range of topics including academic research, technology applications, registration laws and regulations, quality evaluation, clinical studies, clinical applications and market research.

Cooperative projects

In addition to hosting conferences, the IDDA has been cooperating with the China Pharmacopoeia and is involved in discussions related to the

revision of the chapter for inhaled products standards.

In 2014, the IDDA also established technological cooperation with the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS), Inhalation Asia, Respiratory Drug Delivery (RDD) and other international groups. The IDDA attended and presented at both the RDD Asia Conference in 2014 and the 2014 Inhaled Drug Delivery Conference in London.

Future plans

Looking to the future, the IDDA will continue to closely communicate with the China Food and Drug Administration (CFDA), the Chinese Pharmacopoeia Commission and other recognized international organizations to promote the improvement of inhalation drug quality, regulatory standards and inhalation therapy.

The work plan for 2015 includes the Chinese translation and publication of the book *Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products*, publication of a



supplemental issue on inhalation technology in the Chinese Journal of Pharmaceuticals, cooperation with China Food and Drug Administration Center for Drug Evaluation (CFDA CDE) and the Chinese Pharmacopeia Commission to promote the inhaled drug regulation and quality requirements to international standards, and a role in organizing the Inhalation Asia 2015 conference to be held in Shenyang, China, September 9-11, 2015.

More information related to the Inhalation Drug Delivery Association can be found at www.idda.com.cn or by emailing IDDChina@126.com.

Anny Shen, MD is a founder of the IDDA and the Managing Director of Bering Scientific Information China. Tel: 0086 25 52411179, shendl60529@aliyun.com.

For more information on Inhalation Asia 2015, please see the article on page 20 in this issue of *Inhalation* and visit the conference website: www.inhalationasia.org.